ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib is a second-generation Abl inhibitor that was approved for the treatment of chronic myelogenous leukemia by the U.S. Food and Drug Administration (FDA) in 2007 [21].